Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDT/Boston Scientific IND filing for drug/catheter combo slated for fourth quarter.

This article was originally published in The Gray Sheet

Executive Summary

PDT, INC./BOSTON SCIENTIFIC IND FILING ON DRUG/CATHETER SYSTEM FOR PROSTATE DISEASE is slated for the fourth quarter of this year, PDT says. The drug/catheter combination product, which employs photodynamic therapy to treat benign prostatic hyperplasia and prostate cancer, could enter clinicals by the end of the year following approval of the investigational new drug application, according to the company.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT004191

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel